FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody

Second- and third-generation drugs for immuno-oncology treatment—The more the better?

(2017) Wolfram C.M. Dempke et al.   EUROPEAN JOURNAL OF CANCER

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

(2017) Di Zhang et al.   mAbs

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody

(2016) Di Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence

(2015) Régis Joulia et al.   Nature Communications

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

(2014) Yannick Bulliard et al.   IMMUNOLOGY AND CELL BIOLOGY

Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies

(2014) Zhijie Jey Cheng et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization

(2014) Ann L. White et al.   JOURNAL OF IMMUNOLOGY

Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions

(2014) Michael D. Diem et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

(2014) Ross Stewart et al.   Journal for ImmunoTherapy of Cancer

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

(2013) Yannick Bulliard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function

(2013) K. S. Voo et al.   JOURNAL OF IMMUNOLOGY

Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27-Transgenic Mice

(2013) L.-Z. He et al.   JOURNAL OF IMMUNOLOGY

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

(2013) Omid Vafa et al.   METHODS

Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo

(2013) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The decidual stromal cells-secreted CCL2 induces and maintains decidual leukocytes into Th2 bias in human early pregnancy

(2012) Yin-Yan He et al.   CLINICAL IMMUNOLOGY

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc  receptor engagement

(2012) F. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design of novel FN3 domains with high stability by a consensus sequence approach

(2012) S. A. Jacobs et al.   PROTEIN ENGINEERING DESIGN & SELECTION

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling

(2010) Janet Jackman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

(2008) Seung Y. Chu et al.   MOLECULAR IMMUNOLOGY